Compare Amgen, Inc. (AMGN) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Qurate Retail Inc Series A — how do they compare? Amgen, Inc. trades at $366.75 (market cap $196.12B), while Qurate Retail Inc Series A trades at $0.09 (market cap $974.68K). The key difference: Amgen, Inc. is far larger — about 201214.8× Qurate Retail Inc Series A's market cap, and Amgen, Inc. pays a 2.77% dividend while Qurate Retail Inc Series A pays none. Which is the better fit depends on your goals.
| AMGN | QVCAQ | |
|---|---|---|
Market Cap | $196.12B | $974.68K |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $15.03 |
52-Week Low | $271.18 | $0.07 |
Enterprise Value | $241.41B | $4.73B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
QVCAQ trades at $0.0911, down 10.69% on the day, reflecting persistent bearish sentiment. The stock shows mixed earnings performance with one beat and three misses in recent quarters, while financials reveal declining revenue and negative net income margins. Cash flow trends are volatile, with significant financing activities offsetting weak operations. The balance sheet indicates negative shareholder equity and rising debt-to-asset ratios, signaling financial stress. Recent news highlights QVC's 40th anniversary and partnership with TikTok Shop, aiming to revitalize its live shopping brand.
The outlook remains challenging due to sustained losses, high leverage, and competitive pressures in retail. Investment opportunities are limited without a clear path to profitability, though low P/B and P/E ratios may attract value hunters. Key risks include liquidity constraints, debt servicing burdens, and execution missteps in digital transformation efforts. Investors should await concrete turnaround evidence before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
